Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05426005 | Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | active not recruiting | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT03657641 | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 73 | University of Southern CaliforniaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02403505 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer(CEA+RC-BCG) | active not recruiting | Phase 1 | 20 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04484909 | NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT05546879 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC(Liver-NET1) | active not recruiting | Phase 1 | 43 | University Hospital, GrenobleOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT05667298 | Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer(OPERARADIO) | active not recruiting | Phase 1 | 11 | University of ManitobaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 87 | Idience Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT04220827 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | active not recruiting | Phase 1 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06654297 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas | active not recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT07491159 | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | active not recruiting | Phase 1 / Phase 2 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | active not recruiting | Phase 1 / Phase 2 | 48 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05382364 | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | active not recruiting | Phase 1 | 25 | PfizerINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2026source: clinicaltrials